Sunrise's sleep apnea detection tool receives FDA 510(k) clearance
15 Feb 2023
Preview
Source: mobihealthnews
Photo: Westend61/Getty Images
Belgian sleep-focused digital health startup Sunrise received FDA 510(k) clearance for its home sleep apnea test that's placed on a user's chin at night.
The test utilizes a sensor that analyzes bio-signals from mandibular jaw movements, which can help calculate respiratory disturbance often found in sleep apnea patients. It also evaluates airflow and oximetry during sleep to aid in diagnosing sleep-related breathing disorders and sleep apnea.
Results are then sent to an AI-enabled app that analyzes the data, which users can share with a healthcare provider via an online portal.
THE LARGER TREND
Professional sleep apnea tests often involve overnight monitoring at a sleep center, but home testing companies have emerged that allow patients to test for this disorder at home.
In 2021, UK-based wearable medical device company Acurable's AcuPebble SA100 received FDA 510(k) clearance. The device senses, records and interprets physiological signals, like a patient's respiratory pattern, while they sleep to prescreen for obstructive sleep apnea.
ASX-listed ResApp Health also received 510(k) clearance for SleepCheckRx, a mobile sleep apnea screening app that screens for the condition by analyzing breathing and snoring sounds recorded via phone.
Tags: Sunrise, sleep apnea
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.